|Mr. Sean E. Brynjelsen||Pres, CEO & Director||692.12k||N/A||1972|
|Mr. James R. Gruber CPA||CFO, Treasurer & Sec.||N/A||N/A||1972|
|Mr. David Krempa||Sr. VP of Bus. Devel. & Investor Relations||N/A||N/A||N/A|
|Ms. Ingrid Hoos||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
|Mr. Kevin Guthrie||Exec. VP of Commercial Operations||N/A||N/A||N/A|
|Mr. Scott Grossenbach||VP of Sales & Marketing||N/A||N/A||N/A|
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.